TIDMABDX
Abingdon Health PLC
20 March 2023
Abingdon Health plc
("Abingdon Health" or "the Company")
Senzo and Abingdon Health enter into strategic partnership
Abingdon Health's CDMO service to support Senzo in leveraging
its innovative, high-accuracy Amplified Lateral Flow (ALF)
point-of-care diagnostics platform technology across multiple
product opportunities
Senzo Health Limited (London, UK) ("Senzo") and Abingdon Health
plc (York, UK) ("Abingdon Health") announce the signing of a
strategic partnership agreement.
Under the terms of the partnership Abingdon Health will support
Senzo by providing contract development and manufacturing ("CDMO")
services to Senzo and its partners to enable them to develop and
manufacture new rapid tests utilising Senzo's cutting-edge ALF
platform.
Senzo is a leading innovator in the rapid diagnostics testing
market, with its revolutionary lateral flow technology delivering
the same accuracy as laboratory-based PCR with results available
within 10 minutes, at a fraction of the cost. Senzo Health's
technology is initially being applied to the development of a
Covid-19 antigen assay, a broader respiratory panel, and other
infectious disease tests. However, there are a wide range of
applications across clinical, animal health, food, plant pathogen
and environmental testing that would benefit from strengths of
Senzo's platform technology. This strategic partnership will allow
Senzo's partners to accelerate product development through access
to Abingdon Health's CDMO services.
Abingdon Health is a leading lateral flow CDMO offering its
services to an international customer base across a range of
industry sectors. Abingdon Health has the internal capabilities to
take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success". All
projects are managed through Abingdon Health's quality management
system and its services include feasibility, optimisation,
technical transfer, manufacturing, regulatory and commercial
support. Its UK-based automated manufacturing operations are
capable of producing tens of millions of lateral flow tests per
annum.
Jeremy Stackawitz, CEO of Senzo Health, commented: "This new
partnership, with such an established, innovative, and trusted
group as Abingdon, is a terrific opportunity for Senzo as we seek
to expand the tests being developed and brought to market on our
game-changing ALF platform. Collaborating with Abingdon creates a
valuable synergy for customers looking to bring innovative,
high-performance lateral flow products to market, and we're
extremely eager to get to work on the first assays."
Chris Yates, CEO of Abingdon Health, commented: "We are really
excited to be working with Senzo and supporting them in leveraging
their cutting-edge lateral flow platform technology across multiple
applications. We believe this strategic partnership agreement
provides Senzo Health and its customers with access to Abingdon's
best-in-class CDMO service to enable accelerated product
development and time to market."
Enquiries
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
About Senzo :
Senzo is an in vitro diagnostics company developing innovative,
accurate, and accessible testing products. Senzo was founded with
the vision of utilizing novel technologies, with a focus on
enhanced sensitivity, to create mobile, point-of-care and
self-testing products and devices with the ability to accurately,
quickly, and cost-effectively conduct testing where healthcare
professionals and patients need it most. Senzo is creating
game-changing products and systems which bring testing to the
patient, eliminating the need for the current slow, expensive
central-lab testing paradigms. With insights generated at the point
of care, patients can make better decisions faster, and healthcare
professionals can identify life-threatening diseases at an earlier
stage, improving treatment outcomes and saving lives.
www.senzo.com
About Abingdon Health plc:
Abingdon Health is a leading lateral flow contract development
and manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an
ecommerce platform that offers a range of self-tests to empowers
consumers to manage their own health and wellbeing. The Abingdon
Simply Test ecommerce site offers consumers a range of information
to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland such
as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUQAWUPWGQM
(END) Dow Jones Newswires
March 20, 2023 03:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jul 2023 to Jul 2024